Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Antaitavir Hasophate · 1 trial · 1 indication
To investigate the pharmacokinetics of total radioactivity in plasma after oral \[14C\] Antaitavir Hasophate in healthy subjects, and the distribution ratio of total radioactivity in whole blood and plasma
Percent (%) of each radiolabeled drug-related material (parent and each metabolite) will be determined in plasma, urine and feces.
| Arm | Type | Description |
|---|---|---|
| [14C] Antaitavir Hasophate | EXPERIMENTAL | Eligible healthy male subjects received a single oral 100 mg (radioactivity of 200µCi) dose of \[14C\] Antaitavir Hasophate |
| Name | Type | Description |
|---|---|---|
| [14C] Antaitavir Hasophate | DRUG | 100 mg suspension containing 200µCi of \[14C\] Antaitavir Hasophate |
Inclusion Criteria: * signing of informed consent * Weight: Body mass index (BMI) is 19.0\~28.0 kg/m2 * Subjects are able to communicate well with the investigators and be able to complete the trial according to the process Exclusion Criteria: * Those who are known to have allergy history or alle...
Antaitavir Hasophate is an investigational small molecule being studied in healthy male subjects. It is not approved for any disease and is currently in clinical development. The only completed trial was an ADME study, which evaluates how the drug is absorbed, distributed, metabolized, and excreted in the body.
Antaitavir Hasophate is being developed by Sunshine Biopharma Inc., a company listed on the stock exchange under the ticker SBFM. The company is conducting clinical research on this investigational small molecule drug.
Antaitavir Hasophate is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains under investigation.
Antaitavir Hasophate has one completed Phase 1 clinical trial with the identifier NCT05446233. The study was an ADME study of [14C] Antaitavir Hasophate in healthy male subjects, conducted in China with 6 participants aged 18 years and older.
Antaitavir Hasophate is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial. The drug is still in clinical development and has not received regulatory approval for any use.